Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Geoff O Gillard"'
Autor:
Geoff O Gillard, Jennifer L Proctor, Sharon L. Hyzy, Catherine Rhee, Elizabeth W. Scadden, Matthias Nahrendorf, David T. Scadden, Karin Gustafsson, Vanessa Frodermann, Michael P. Cooke, Anthony E. Boitano, Rahul Palchaudhuri
Publikováno v:
Blood. 136:34-35
Cardiovascular disease (CVD) is the leading cause of death worldwide. Recently, age-related clonal hematopoiesis (CH) has been recognized as a risk factor for CVD of comparable magnitude to smoking, hypertension and hypercholesteremia. While these ot
Autor:
Nicholas M. Clark, Hans-Peter Kiem, Anthony E. Boitano, Jennifer L. Proctor, Katelyn J. Hammond, Charlotte Mcdonagh, Anjali Bhat, Geoff O Gillard, Rahul Palchaudhuri, Tahirih L. Lamothe, Ganapathy N. Sarma, Sharon L. Hyzy, Bradley R. Pearse, Bruce R. Blazar, John C. Davis, John E. Wagner, Michael P. Cooke, Asim Saha
Publikováno v:
Blood. 136:31-31
Introduction Allogeneic hematopoietic stem cell transplant (Allo-HSCT) is a potentially curative treatment for malignant and non-malignant blood disorders. However, current conditioning regimens limit the use of this curative procedure in many eligib
Autor:
Jennifer L Proctor, Vanessa Frodermann, Rahul Palchaudhuri, Michael Cook, Karin Gustafsson, Geoff O Gillard, Matthias Nahrendorf, Tony Boitano, David T. Scadden, Catherine Rhee
Publikováno v:
Experimental Hematology. 88:S32
Clonal hematopoiesis (CH) is an age-related phenomenon linked to increases in cardiac mortality, all-cause mortality and myeloid malignancies. The magnitude of risk rivals that of known risk factors like high cholesterol or hypertension. Unlike those
Autor:
Rahul Palchaudhuri, Ganapathy N. Sarma, Melissa L. Brooks, Bradley R. Pearse, Bruce R. Blazar, Geoff O Gillard, Sharon L. Hyzy, Nicholas M. Clark, Hans-Peter Kiem, Anthony E. Boitano, John E. Wagner, Katelyn J. Hammond, Tahirih L. Lamothe, Asim Saha, Charlotte Mcdonagh, Anjali Bhat, Michael P. Cooke, Jennifer L. Proctor
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S160
Introduction Allogeneic hematopoietic stem cell transplant (Allo-HSCT) is a potentially curative treatment for malignant and non-malignant blood disorders. However, current conditioning regimens limit its use due to regimen-related mortality and morb
Autor:
Anjali Bhat, Michael P. Cooke, Oliver Mikse, Prashant raj Bhattarai, Charlotte F. Mcdonough, Geoff O Gillard, Tahirih L. Lamothe, Sharon L. Hyzy, Rahul Palchaudhuri, Ganapathy N. Sarma, Bradley R. Pearse, Jennifer L. Proctor, Anthony E. Boitano, Sean McDonough, Melissa L. Brooks, Pranoti Sawant
Publikováno v:
Blood. 134:3208-3208
Resetting the immune system through autologous hematopoietic stem cell transplant (autoHSCT) is a highly effective treatment in selected patients with autoimmune diseases. AutoHSCT can induce long-term remission (up to 15 years) with 70-80% progressi
Autor:
Andrew D Gabros, Olga Burenkova, Charlotte Mcdonagh, Brad R. Pearse, Anthony E. Boitano, Melissa L. Brooks, Rahul Palchaudhuri, Hillary L. Adams, Ganapathy N. Sarma, Michael P. Cooke, Sharon Aslanian, Jennifer L. Proctor, Geoff O Gillard, Sharon L. Hyzy, Tahirih L. Lamothe
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S188-S189
Bone Marrow Transplant (BMT) is a potentially curative treatment for malignant and non-malignant blood disorders. Current regimens for patient preparation, or conditioning, prior to BMT limit the use of this curative procedure due to regimen-related
Autor:
Andrew D Gabros, Brad R. Pearse, Lena Kien, Geoff O Gillard, Sharon L. Hyzy, Anthony E. Boitano, Anjali Bhat, Rahul Palchaudhuri, Sean McDonough, Jennifer L. Proctor, Charlotte Mcdonagh, Junia Dushime, Ganapathy N. Sarma, Danielle Ladwig, Patrick C. Falahee, Nidhi Jain, Michael P. Cooke, Tahirih L. Lamothe, Pranoti Sawant, Hillary L. Adams, Qing Li, Sharon Aslanian, Rajiv Panwar
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S32
Introduction Bone Marrow Transplant (BMT) is a potentially curative treatment for malignant and non-malignant blood disorders. Current regimens for patient preparation, or conditioning, prior to BMT limit the use of this curative procedure due to reg
Autor:
Rajiv Panwar, Sean McDonough, Geoff O Gillard, Qing Li, Anthony E. Boitano, Charlotte Mcdonagh, Sharon Aslanian, Hillary L. Adams, Sharon L. Hyzy, Andrew D Gabros, Anjali Bhat, Molly A McShea, Pranoti Sawant, Rahul Palchaudhuri, Danielle Ladwig, Patrick C. Falahee, Ganapathy N. Sarma, Lena Kien, Michael P. Cooke, Bradley R. Pearse, Tahirih L. Lamothe, Jennifer L. Proctor, Junia Dushime, Nathan M Kallen, Melissa L. Brooks
Publikováno v:
Blood. 132:4526-4526
Introduction Bone Marrow Transplant (BMT) is a potentially curative treatment for malignant and non-malignant blood disorders and has demonstrated impressive outcomes in autoimmune diseases. Prior to BMT, patients are prepared with high-dose chemothe